Current status of clinical trials of HPV therapeutic vaccines.
10.3760/cma.j.cn112150-20221026-01037
- VernacularTitle:人乳头瘤病毒治疗性疫苗临床试验研究进展
- Author:
Min Yi WANG
1
;
Yi Na CUN
1
Author Information
1. Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, China.
- Publication Type:Journal Article
- MeSH:
Female;
Humans;
Papillomavirus Vaccines/therapeutic use*;
Papillomavirus Infections/prevention & control*;
Uterine Cervical Neoplasms;
Immunity, Cellular;
Papillomaviridae
- From:
Chinese Journal of Preventive Medicine
2023;57(10):1647-1654
- CountryChina
- Language:Chinese
-
Abstract:
Cervical cancer mainly caused by human papillomavirus (HPV) infection has become a public health issue, which seriously threatens women 's health. To prevent HPV infection, the currently used prophylactic vaccines mainly induce a humoral immune response in the host, thereby generating neutralizing antibodies. In contrast, the design goal of therapeutic HPV vaccines is to induce a cell-mediated immune response in the host, primarily driven by Th1 cells, aiming to clear existing viral infections and slow down or inhibit tumor progression. Currently, several therapeutic HPV vaccines based on different mechanisms and techniques have entered clinical trials. This review will summarize the progress of these clinical trials, providing reference for the research and development of therapeutic HPV vaccines.
